NPEPPS is a novel and druggable driver of platinum resistance
Robert T. Jones(MedStar Franklin Square Medical Center), James C. Costello(University of Colorado Cancer Center)
Cited by 1
Related Papers
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
|Cancer Discovery|2020|550
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
|Nature Genetics|2013|374
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
|Communications Biology|2020|170
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
|Science Advances|2019|126
ImmGen at 15
|Nature Immunology|2020|79